These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38154557)

  • 1. Glomerular transcriptomics predicts long term outcome and identifies therapeutic strategies for patients with assumed benign IgA nephropathy.
    Rivedal M; Mikkelsen H; Marti HP; Liu L; Kiryluk K; Knoop T; Bjørneklett R; Haaskjold YL; Furriol J; Leh S; Paunas F; Bábíčková J; Scherer A; Serre C; Eikrem O; Strauss P
    Kidney Int; 2024 Apr; 105(4):717-730. PubMed ID: 38154557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Precocious activation of genes of the renin-angiotensin system and the fibrogenic cascade in IgA glomerulonephritis.
    Del Prete D; Gambaro G; Lupo A; Anglani F; Brezzi B; Magistroni R; Graziotto R; Furci L; Modena F; Bernich P; Albertazzi A; D'Angelo A; Maschio G
    Kidney Int; 2003 Jul; 64(1):149-59. PubMed ID: 12787405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular profiling in IgA nephropathy and focal and segmental glomerulosclerosis.
    Tycová I; Hrubá P; Maixnerová D; Girmanová E; Mrázová P; Straňavová L; Zachoval R; Merta M; Slatinská J; Kollár M; Honsová E; Tesař V; Viklický O
    Physiol Res; 2018 Mar; 67(1):93-105. PubMed ID: 29137483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA-Seq profiling of microdissected glomeruli identifies potential biomarkers for human IgA nephropathy.
    Park S; Yang SH; Jeong CW; Moon KC; Kim DK; Joo KW; Kim YS; Lee JW; Lee H
    Am J Physiol Renal Physiol; 2020 Nov; 319(5):F809-F821. PubMed ID: 32954852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sparsentan: the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy.
    Trachtman H; Komers R; Inrig J
    Expert Rev Clin Immunol; 2024 Jun; 20(6):571-576. PubMed ID: 38362830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of inflammatory biomarkers in IgA nephropathy using the NanoString technology: a validation study in Caucasians.
    Gaumond L; Lamarche C; Beauchemin S; Henley N; Elftouh N; Gerarduzzi C; Laurin LP
    Inflamm Res; 2024 Mar; 73(3):447-457. PubMed ID: 38291238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive analysis of aberrantly expressed profiles of mRNA and its relationship with serum galactose-deficient IgA1 level in IgA nephropathy.
    Liu Y; Liu X; Jia J; Zheng J; Yan T
    J Transl Med; 2019 Sep; 17(1):320. PubMed ID: 31547815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with progression of IgA nephropathy are related to renal function--a model for estimating risk of progression in mild disease.
    Rauta V; Finne P; Fagerudd J; Rosenlöf K; Törnroth T; Grönhagen-Riska C
    Clin Nephrol; 2002 Aug; 58(2):85-94. PubMed ID: 12227693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sparsentan is superior to losartan in the gddY mouse model of IgA nephropathy.
    Nagasawa H; Ueda S; Suzuki H; Jenkinson C; Fukao Y; Nakayama M; Otsuka T; Okuma T; Clapper W; Liu K; Nguyen M; Komers R; Suzuki Y
    Nephrol Dial Transplant; 2024 Aug; 39(9):1494-1503. PubMed ID: 38271614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formalin-fixed paraffin-embedded renal biopsy tissues: an underexploited biospecimen resource for gene expression profiling in IgA nephropathy.
    Cox SN; Chiurlia S; Divella C; Rossini M; Serino G; Bonomini M; Sirolli V; Aiello FB; Zaza G; Squarzoni I; Gangemi C; Stangou M; Papagianni A; Haas M; Schena FP
    Sci Rep; 2020 Sep; 10(1):15164. PubMed ID: 32938960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential expression of microRNA miR-150-5p in IgA nephropathy as a potential mediator and marker of disease progression.
    Pawluczyk IZA; Didangelos A; Barbour SJ; Er L; Becker JU; Martin R; Taylor S; Bhachu JS; Lyons EG; Jenkins RH; Fraser D; Molyneux K; Perales-Patón J; Saez-Rodriguez J; Barratt J
    Kidney Int; 2021 May; 99(5):1127-1139. PubMed ID: 33417998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of Bcl-2 by podocytes is associated with progressive glomerular injury and clinical indices of poor renal prognosis in human IgA nephropathy.
    Qiu LQ; Sinniah R; I-Hong Hsu S
    J Am Soc Nephrol; 2004 Jan; 15(1):79-90. PubMed ID: 14694160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defective gene expression of the membrane complement inhibitor CD46 in patients with progressive immunoglobulin A nephropathy.
    Coppo R; Peruzzi L; Loiacono E; Bergallo M; Krutova A; Russo ML; Cocchi E; Amore A; Lundberg S; Maixnerova D; Tesar V; Perkowska-Ptasińska A; Durlik M; Goumenos D; Gerolymos M; Galesic K; Toric L; Papagianni A; Stangou M; Mizerska-Wasia Membek M; Gesualdo L; Montemurno E; Benozzi L; Cusinato S; Hryszko T; Klinger M; Kamińska D; Krajewska M;
    Nephrol Dial Transplant; 2019 Apr; 34(4):587-596. PubMed ID: 29635535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sparsentan: A First-in-Class Dual Endothelin and Angiotensin II Receptor Antagonist.
    Chiu AW; Bredenkamp N
    Ann Pharmacother; 2024 Jun; 58(6):645-656. PubMed ID: 37706310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arteriolar C4d in IgA Nephropathy: A Cohort Study.
    Faria B; Canão P; Cai Q; Henriques C; Matos AC; Poppelaars F; Gaya da Costa M; Daha MR; Silva R; Pestana M; Seelen MA
    Am J Kidney Dis; 2020 Nov; 76(5):669-678. PubMed ID: 32439421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
    Li S; Li JP
    Trials; 2020 Jan; 21(1):31. PubMed ID: 31907076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered mRNA expression in renal biopsy tissue from patients with IgA nephropathy.
    Waga I; Yamamoto J; Sasai H; Munger WE; Hogan SL; Preston GA; Sun HW; Jennette JC; Falk RJ; Alcorta DA
    Kidney Int; 2003 Oct; 64(4):1253-64. PubMed ID: 12969143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying potential biomarkers for the diagnosis and treatment of IgA nephropathy based on bioinformatics analysis.
    Li X; Zeng M; Liu J; Zhang S; Liu Y; Zhao Y; Wei C; Yang K; Huang Y; Zhang L; Xiao L
    BMC Med Genomics; 2023 Mar; 16(1):63. PubMed ID: 36978098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Replication of genome-wide association study identified seven susceptibility genes, affirming the effect of rs2856717 on renal function and poor outcome of IgA nephropathy.
    Wang W; Li G; Hong D; Zou Y; Fei D; Wang L
    Nephrology (Carlton); 2017 Oct; 22(10):811-817. PubMed ID: 27450519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The molecular phenotype of endocapillary proliferation: novel therapeutic targets for IgA nephropathy.
    Hodgin JB; Berthier CC; John R; Grone E; Porubsky S; Gröne HJ; Herzenberg AM; Scholey JW; Hladunewich M; Cattran DC; Kretzler M; Reich HN
    PLoS One; 2014; 9(8):e103413. PubMed ID: 25133636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.